2016•Clinical Medicine (Russian Journal)Requires access

Pneumococcal vaccine in adults reduces the risk of infections caused by Streptococcus pneumoniae

Yulia G. Belocerkovskaja, A. G. Romanovskih, Е А Стырт

Abstract

Streptococcus pneumoniae is a major cause of severe disease worldwide, particularly in the risk population. Two pneumococcal vaccines are currently available for specific prevention of pneumococcal infections among adults in Russia: a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13). The article describes modern views on the effectiveness and safety of two pneumococcal vaccines in adults with underlying medical conditions and adults aged ≥ 65 years and provides current recommendations for routine use of PPSV23 and PCV13 among persons included in the risk group.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Medicine, Streptococcus pneumoniae, Pneumococcal polysaccharide vaccine, Pneumococcal vaccine, Pneumococcal conjugate vaccine, Pneumococcal infections, Pneumococcal disease, Immunology